NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
19 Nov 2020

CorWave Secures a €500,000 Grant From the Paris Region for Its Industrial Facilities

CorWave has won the call for projects “Industry Stimulus Plan” operated by the Paris Region.
18 Nov 2020

Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has cleared Vivet’s Investigational New Drug (IND) application for the GATEWAY study.
16 Nov 2020

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

Preclinical data highlights potential therapeutic action and protection against neurodegeneration.
12 Nov 2020

AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

AM-Pharma B.V., an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, today announced that it has enrolled the first patient in its global Phase III trial named REVIVAL.
Galecto Announces Pricing of Initial Public Offering<
12 Nov 2020

Galecto Announces Pricing of Initial Public Offering

The shares are expected to begin trading on the Nasdaq Global Market on October 29, 2020 under the ticker symbol “GLTO
30 Oct 2020

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

Minoryx Therapeutics today announces that the European Investment Bank (EIB) has approved a €25 million financing.
29 Oct 2020

SparingVision Strengthens Management Team

SparingVision today announces the strengthening of its senior management team with the appointment of Dr. Florence Lorget as Chief Development Sciences Officer (“CDSO”) and Dr. Rajiv Gangurde as Chief Technology Officer (“CTO”).
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease<
27 Oct 2020

Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

First Approved Prescription Therapy Specifically for Short-Term Treatment of Dry Eye Disease
SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer<
21 Oct 2020

SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer

Ysios Capital joins SparingVison 44.5M€ financing round.
12 Oct 2020

Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020

Sanifit announced that it will present new data on its lead asset SNF472 at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting on October 22, 2020.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.